Biom'Up

Equities

BUP

FR0013284080

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

2020	Biom’Up Appoints Stéphanie Boileau-Canu as Chief Financial Officer	CI
2020	Biom’Up Expands Management Team	CI

Biom'up Announces Consolidated Earnings Results for the Year of 2018

April 30, 2019 at 02:00 am EDT

Biom'up announced consolidated earnings results for the year of 2018. For the year of 2018, the company reported revenues of €1,176,000 compared to €1,766,000 a year ago. Operating loss was €38,275,000 compared to €17,713,000 a year ago. Net loss of consolidated operations was €40,590,000 compared to €31,283,000 a year ago.

Latest news about Biom'Up

Biom’Up Appoints Stéphanie Boileau-Canu as Chief Financial Officer	20-09-02	CI
Biom’Up Expands Management Team	20-09-02	CI
Biom’Up Announces Plan to Sell Assets to Athyrium	19-12-17	CI
Biom'up Announces the Approval of HEMOBLAST (Tm) Bellows and Its Laparoscopic Applicator in Australia; Reaffirms Revenue Guidance for 2019	19-10-07	CI
Biom'Up S.A. Provides Revenue Guidance for the First Nine Months and Full-Year of 2019	19-09-30	CI
Biom'Up S.A. Announces Executive Changes	19-09-18	CI
Biom'up S.A. Announces Publication of Clinical Case Studies Highlighting the Use of the Company's Lead Novel Hemostatic Product, Hemoblast Bellows in Cardiovascular Procedures	19-08-14	CI
Biom'Up S.A Announces Unaudited Sales Results for the First Half Ended June 30, 2019; Reiterates Revenue Guidance for the Full-Year of 2019	19-07-10	CI
Biom'up S.A. Announces Change in Leadership Position	19-05-31	CI
Biom'up Announces Consolidated Earnings Results for the Year of 2018	19-04-30	CI
Biom'up S.A. Announces U.S. Food and Drug Administration Approves the IDE (Investigational Device Exemption) Application for HEMOSNOW	19-04-24	CI
Biom'up Signs of an Exclusive Distribution Agreement for HEMOBLAST(TM) Bellows in Australia with Life Healthcare Distribution	19-04-15	CI
Biom’Up Appoints George Makhoul as Chief Commercial Officer	19-01-31	CI
Biom'Up S.A. Announces the Publication of Scientific and Clinical Data with its Product HEMOBLAST Bellows	19-01-30	CI
Biom’Up Granted FDA Approval for Its HEMOBLAST™ Bellows Laparoscopic Applicator	19-01-22	CI
Certain Shares of Biom'Up S.A. are subject to a Lock-Up Agreement Ending on 16-JAN-2019.	19-01-15	CI
Certain BSPCE Business Creator Stock Warrants of Biom'Up S.A. are subject to a Lock-Up Agreement Ending on 16-JAN-2019.	19-01-15	CI
Certain BSA Stock Warrants of Biom'Up S.A. are subject to a Lock-Up Agreement Ending on 16-JAN-2019.	19-01-15	CI
Certain Stock Options of Biom'Up S.A. are subject to a Lock-Up Agreement Ending on 16-JAN-2019.	19-01-15	CI
Biom'Up S.A. Announces Achievement of Two Major Development Milestones	19-01-07	CI
Biom'Up S.A. Announces Renewal of the Supply Agreement for Human-Derived Thrombin	19-01-07	CI
Biom'up S.A. Announces the Success of the Partial Issue of the Second Tranche of Bond Financing for EUR 3 Million Out of the EUR 10 Million Available	18-12-31	CI
Biom'up Announces Completion of the 2018 Scale-Up of Its Manufacturing Facility to Meet Commercial Demand for Hemoblast(Tm) Bellows	18-11-08	CI
Biom’up Announces First Distribution Agreement for HEMOBLAST Bellows	18-10-16	CI
Certain BSPCE Business Creator Stock Warrants of Biom'Up S.A. are subject to a Lock-Up Agreement Ending on 11-OCT-2018.	18-10-10	CI

Chart Biom'Up

Duration

Period

More charts

Company Profile

Biom Up SA is a France-based company engaged in the design, development and production of medical devices. The products of the Company are based on biopolymers such as collagen. Biom Up SA markets two lines of products: Cova line (including Cova ORTHO, Cova CARD and Cova MAX, among others), which is a membrane for adhesion prevention and guided healing, and MatriBONE, which is a bone regeneration matrix with haemostatic, absorbable and osteoconductive properties. MatriBONE is used in orthopedic and maxillofacial surgery for the filling of bone defects whether it is from surgical, traumatic or pathological origin. The Company also designs other products, such as dental surgery products and several collagen types, which are developed and manufactured for the Company's partners.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIOM'UP	-.--%	4.51M
ABBOTT LABORATORIES	-3.18%	184B
MEDTRONIC PLC	-1.40%	107B
BECTON, DICKINSON AND COMPANY	-3.50%	67.78B
DEXCOM, INC.	+1.89%	50.66B
CENCORA, INC.	+11.63%	47.64B
HOYA CORPORATION	+4.60%	41.12B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.41%	26.3B
WEST PHARMACEUTICAL SERVICES, INC.	+2.83%	26.04B
TERUMO CORPORATION	+15.06%	25.4B

Other Medical Equipment, Supplies & Distribution